Quantcast

Latest Oncothyreon Inc. Stories

2011-04-28 15:01:00

SEATTLE, April 28 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced its intention to offer, subject to market and other conditions, shares of its common stock in an underwritten public offering. Oncothyreon also expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. The proceeds of the offering will primarily be used to fund the...

2011-04-04 05:00:00

SEATTLE, WA, April 4 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of preclinical data for ONT-10, a therapeutic vaccine directed at cancers expressing MUC1, and PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), at the American Association of Cancer Research meeting in Orlando, Florida. ONT-10 ONT-10 is a therapeutic vaccine targeting MUC1 which has been designed to stimulate both the humoral and cellular arms...

2011-03-29 07:00:00

SEATTLE, WA, March 29 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the Company will be presenting at the following scientific & investor conferences during April: American Association of Cancer Research 102(nd) Annual Conference Preclinical data about ONT-10, Oncothyreon's proprietary, follow-on cancer vaccine, and PX-866, the Company's irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), will be highlighted in the following poster...

2011-03-10 06:00:00

COMPANY TO HOLD CONFERENCE CALL AT 8:00 EST TODAY SEATTLE, WA, March 10 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (the "Company") today reported financial results for the year and quarter ending December 31, 2010.  Net loss for the year ended December 31, 2010 was $15.6 million, or $0.58 per basic and diluted share, compared with net loss of $17.2 million, or $0.76 per basic and diluted share for the year ended December 31, 2009.  The decrease in net loss...

2011-03-01 07:05:00

SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that the company will be presenting at the following industry and investor conferences during March:  -- 11th Annual Life Science Innovation Northwest Conference: Julie Eastland, Oncothyreon's Chief Financial Officer, will present at this life sciences conference in Seattle on Wednesday, March 2 at 1:45 p.m. Pacific Time. -- 22nd Annual...

2011-03-01 07:00:00

SEATTLE, March 1 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced the presentation of preclinical data on PX-866, its irreversible inhibitor of phosphatidylinositol 3-kinase (PI3K), at the American Association of Cancer Research (AACR) Special Conference "Targeting PI3K/mTOR Signaling." PX-866 is an oral, small molecule compound designed to inhibit the activity of PI3K, a component of an important cell survival signaling pathway. Results presented at the...

2011-02-08 07:00:00

SEATTLE, Feb. 8 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 13(th) Annual BIO CEO & Investor Conference in New York on Tuesday, February 15, 2011, at 1:00 p.m. Eastern Time. A live and archived webcast of Dr. Kirkman's presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section. About Oncothyreon...

2010-12-20 07:00:00

SEATTLE, WA, Dec. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced enrollment of the first patient in a Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux(R)). PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K), a component of an important cell survival signaling pathway. The primary objective of the Phase 1 dose-escalation portion of the trial is to...

2010-11-18 07:00:00

SEATTLE, Nov. 18 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY) today reported updated results from a Phase 1 clinical trial of PX-866, an irreversible small molecule phosphatidylinositol-3-kinase (PI-3K) inhibitor, in patients with advanced solid tumors. The results were presented by Antonio Jimeno, M.D., Ph.D., of the University of Colorado Cancer Center, Aurora, Colorado, at the 22(nd) EORTC/NCI/AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Berlin,...

2010-11-08 15:05:00

SEATTLE, Nov. 8 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) today reported a net loss for the quarter ended September 30, 2010 of $4.4 million or $0.17 per basic and diluted share, compared with a net loss of $6.0 million or $0.24 per basic and diluted share for the comparable period in 2009.  Oncothyreon also reported a net loss of $9.5 million or $0.37 per basic and diluted share for the nine months ended September 30, 2010, compared with a net loss of $14.7...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.